		
	Application No.	Applicant(s)
•	09/486,516	REDL ET AL.
Notice of Allowability	Examiner	Art Unit
	Michael V. Meller	1655
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. \boxtimes This communication is responsive to <u>the response filed 1/1</u>	<u>17/2006</u> .	
2. X The allowed claim(s) is/are 29,33,36-42,51,54-60 and 70-7	<u>73</u> .	
 Acknowledgment is made of a claim for foreign priority ur a)	nder 35 U.S.C. § 119(a)-(d) or (f).	
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
Copies of the certified copies of the priority do	cuments have been received in this i	national stage application from the
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.	
(a) ☐ including changes required by the Notice of Draftspers	son's Patent Drawing Review (PTO-	948) attached
1) hereto or 2) to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the O	ffice action of
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P	atent Application (PTO-152)
2. ☐ Notice of Praftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	
	Paper No./Mail Dat	e
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 	8), 7. ⊠ Examiner's Amendn	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	9. 🗆 Other	
		MELLER EXAMINER

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jennifer Wahlsten on 3/30/2006.

The application has been amended as follows:

IN THE CLAIMS:

Claim 29, lines 1-3, delete, "comprising fibrinogen and an admixed......and mixtures thereof" and insert, ---comprising a therapeutically effective amount of fibrinogen and eglin.----

Claims 36-39, line 2, delete, "elastase inhibitor" and insert, ---eglin---.

Claim 60, lines 1-2, delete, "elastase inhibitor" and insert, ---eglin---.

Application/Control Number: 09/486,516

Art Unit: 1655

Claim 70-73 are no longer withdrawn and are now pending, rejoined and examined claims.

Claim 70, lines 2-4, delete, "a tissue adhesive preparation containing fibrinogen.....and mixtures thereof" and insert, ----the tissue adhesive preparation of claim 29.---

Claim 72, lines 2-3, delete, "a tissue adhesive containing fibrinogen and an elastase inhibitor" and insert, ---the tissue adhesive of claim 29---.

The following is an examiner's statement of reasons for allowance: there is no art of record which anticipates the claims. Applicant's unexpected results of eglin and fibrinogen used together in the specification has been reconsidered. Since applicant has shown unexpected results using eglin and fibrinogen together as noted in applicant's appeal brief, the rejections under 35 USC 103 are withdrawn due to the unexpected results that applicant has attained using the combination of eglin and fibrinogen.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael V. Meller whose telephone number is 571-272-0967. The examiner can normally be reached on Monday thru Thursday: 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael V. Meller Primary Examiner Art Unit 1655

MVM